In chemotherapy for lung cancer, sometimes less is more

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 3, 2013, Pages 232-235

  Roeland, Eric ^a   Loprinzi, Charles ^b   Moynihan, Timothy J ^b   Smith, Thomas J ^c   Temel, Jennifer ^d  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MAYO CLINIC   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CRIZOTINIB; ERLOTINIB; PEMETREXED; PLATINUM; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; NOTE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; QUALITY OF LIFE; TREATMENT RESPONSE;

EID: 84875896027     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0034     Document Type: Note

References (32)

1. Massarelli E, Andre F, Liu D, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003;39:55-61.
2. Shanafelt TD, Loprinzi C, Marks R, et al. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004;22:1966-1974.
3. Langer C, Li S, Schiller J, et al. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group Performance Status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 2007;25:418-423.
4. Radzikowska E, Glaz P, Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002;13:1087-1093.
5. Gridelli C. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004;15:419-426.
6. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266.
7. Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740-801.
8. Riely GJ, Chaft JE, Ladanyi M, et al. Incorporation of crizotinib into the NCCN guidelines. J Natl Compr Canc Netw 2011;9:1328-1330.
9. Earle CC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2003;22:315-321.
10. Ho TH, Barbera L, Saskin R, et al. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol 2011;29:1587-1591.
11. Murillo JR, Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 2006;11:1095-1099.
12. Emanuel EJ, Young-Xu Y, Levinsky NG, et al. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 2003;138:639-643.
13. Connor SR, Pyenson B, Fitch K, et al. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage 2007;33:238-246.
14. Saito A, Landrum MB, Neville B, et al. The effects on survival of continuing chemotherapy to near death. BMC Palliat Care 2011;10:14.
15. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-742.
16. Colby WH, Dahlin C, Lantos J, et al. The National Consensus Project for Quality Palliative Care Clinical Practice Guidelines Domain 8: ethical and legal aspects of care. HEC Forum 2010;22:117-131.
17. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
18. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
19. Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 2009;302:741-749.
20. Connor SR, Pyenson B, Fitch K, et al. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage 2007;33:238-246.
21. Greer JA, McMahon PM, Tramontano A, et al. Effect of early palliative care on health care costs in patients with metastatic NSCLC [abstract]. J Clin Oncol 2012;30(Suppl):Abstract 6004.
22. Asahina H, Sekine I, Horinouchi H, et al. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2012;13:39-43.
23. Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003;39:55-61.
24. Shanafelt TD, Loprinzi C, Marks R, et al. Are chemotherapy response rates related to treatment-induced survival prolongations in patients with advanced cancer? J Clin Oncol 2004;22:1966-1974.
25. Saito AM, Landrum MB, Neville BA, et al. The effect on survival of continuing chemotherapy to near death. BMC Palliat Care 2011;10:14.
26. Saito AM, Landrum MB, Neville BA, et al. Hospice care and survival among elderly patients with lung cancer. J Palliat Med 2011;14:929-939.
27. Nelson JE, Gay EB, Berman AR, et al. Patients rate physician communication about lung cancer. Cancer 2011;117:5212-5220.
28. Huskamp HA, Keating NL, Malin JL, et al. Discussions with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med 2009;169:954-962.
29. Christakis NA, Lamont EB, Smith JL, et al. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ 2000;320:469-472.
30. Steensma D, Loprinzi C: The art and science of prognosis in patients with advanced cancer. Eur J Canc 2000;36:2025-2027.
31. Panagopoulou E, Panagopoulou E, Panagopoulou E, et al. Concealment of information in clinical practice: is lying less stressful than telling the truth? J Clin Oncol 2008;26:1175-1177.
32. Keating NL, Landrum MB, Rogers SO Jr, et al. Physician factors associated with discussions about end-of-life care. Cancer 2010;116:998-1006.